Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03005626
Other study ID # 9752
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2017
Est. completion date November 16, 2020

Study information

Verified date November 2022
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Investigators aim to measure the impact of a transition program in congenital cardiology in terms of health-related quality of life.


Description:

The number of adults with congenital heart diseases (CHD) is increasing. However, many young adults are lost to follow-up even in experienced tertiary care centers. American and European guidelines recommend to improve the management of young adults with CHD. Structured therapeutic education programs are therefore needed to optimize the transfer to adult healthcare. Our tertiary care CHD center recently implemented a transition program and simultaneously investigators decided to measure its impact. Indeed investigators need data from randomized trials in this filed. After previous controlled quality of life studies among children and adults with CHD, investigators chose to use the health-related quality of life (HR-QoL) as primary endpoint in this randomized study to focus on patient related outcomes. The investigators assume that patients who participate in this program will improve their quality of life compared to controls. If investigators demonstrate the benefit of this program, it will have important consequences for patients with CHD and eventually for patients with other chronic medical conditions.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date November 16, 2020
Est. primary completion date November 16, 2020
Accepts healthy volunteers No
Gender All
Age group 13 Years to 25 Years
Eligibility Inclusion Criteria: - Patient from 13 years to 25 years inclusive. - Carrying of Congenital Heart Disease as defined in the International Classification. - Possible follow-up for one year on one of the three hospital center. - Informed consent of the patient for adults and, parents or legal guardians for minors. - Affiliation to a social security system. Exclusion Criteria: - Non-francophone, - Severe intellectual impairment.

Study Design


Intervention

Other:
Therapeutic education

Standard follow-up


Locations

Country Name City State
France Pediatric and Congenital Cardiology and Pulmonology Department, Arnaud De Villeneuve University Hospital Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary PedsQL 4.0 score Evolution of the quality of life assessed by PedsQL 4.0 self-reported scores from month 0 to month 12. Follow up of patients over 12 months
Secondary Physiological parameters Evolution of the physiological parameters during a cardiopulmonary exercise test performed on a treadmill according to a modified Bruce protocole. Evolution of the physiological parameters from month 0 to month 12 Follow up of patients over 12 months
Secondary Ricci and Gagnon score Evolution of the physical activity assessed by Ricci and Gagnon scores from month 0 to month 12. Ricci and Ganon score is a physical activity self-questionnaire with a total score out of 40 (<16 points: not very active, between 16 and 32 points: fairly active, > 32 points: very active). Follow up of patients over 12 months
Secondary Leuven Knowledge score Evolution of the knowledge of the disease assessed by Leuven Knowledge scores from month 0 to month 12. The level of knowledge was assessed by the "transition readdiness assessment" instrument : 10-item questionnaire reflecting the basic knowledge of the diseases and its management. Follow up of patients over 12 months
Secondary Disease severity The evolution of the severity of the disease from month 0 to month 12 was assessed by the degree of heart failure (NYHA functionnal class I to IV) and the number of hospitalizations (in stays and days) for complications related to the congenital heart disease Follow up of patients over 12 months
Secondary Anxiety and depression The evolution of the levels of depression and/or anxiety from month 0 to month 12 was assessed respectively by :
the BDI (Beck Depression Inventory) for young adults
the CDI (Child Depression Inventory) for adolescents
the STAI (State and Trait Anxiety Inventory) for adults and STAI-C (Children) for adolescents.
A higher score is associated with a higher risk of depression/anxiety.
Follow up of patients over 12 months
See also
  Status Clinical Trial Phase
Unknown status NCT01450956 - The Protective Effects of Sevoflurane in Pediatric Cardiac Surgery N/A
Recruiting NCT02503267 - "Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects" N/A
Terminated NCT03437148 - Non-Invasive Shunt Quantification in Interatrial Communication N/A
Active, not recruiting NCT06223321 - The Role of Multislice Computed Tomography in Congenital Heart Diseases in Paediatric Age Group.
Completed NCT01619982 - Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients Phase 4
Recruiting NCT02542683 - Physical Activity and Cognitive Development in Children
Enrolling by invitation NCT02527811 - Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery Phase 4